Precision Medicine News and Research

RSS

Patient's mucus may help predict type of chronic sinusitis

By April, nearly one-third of the U.S. is already experiencing high pollen levels while the weather and temperatures continue to fluctuate, aggravating sinus symptoms. A patient's mucus may predict the type of his or her chronic sinusitis, which could help doctors determine whether surgery or medical treatments can produce the best outcomes, according to a recently published Vanderbilt study.

9 Apr 2018

PET imaging agent may help predict effectiveness of depression treatment

A positron emission tomography imaging agent could show, ahead of time, whether a specific treatment is likely to be effective for major depressive disorder--a debilitating condition that affects more than 14 million Americans.

6 Apr 2018

Ionizing radiation can reduce stiffness of tumor cell microenvironment

Nearly half of all cancer patients receive radiation therapy to curb the growth of malignant cells. But little is known about how ionizing radiation affects the extracellular matrix (ECM), a patchwork of proteins and other biomolecules that surrounds cells and plays a vital role in their shape, movement and signaling functions.

3 Apr 2018

New PET imaging agent could help guide treatments for people with neurological diseases

Researchers have developed a new imaging agent that could help guide and assess treatments for people with various neurological diseases, including Alzheimer's, Parkinson's, and multiple sclerosis.

2 Apr 2018

The Human Microbiome – A New Potential Fingerprint in Forensic Evidence?

Professor Jack Gilbert gives an overview of the Burglary Microbiome Project, which he discussed at Pittcon 2018.

From Pittcon 29 Mar 2018

Combination therapy effectively induces tumor cell death and reduces spread of breast cancer

Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps cancer cells proliferate and grow.

27 Mar 2018

Researchers develop comprehensive map of genetic risk factors for stroke

Stroke is a serious disease affecting blood flow to and from the brain, and is the second leading cause of death worldwide. Stroke is characterized by a sudden onset of neurological dysfunction, caused by a blood clot or hemorrhage in a cerebral artery. While many genetic variants and lifestyle behaviors have been identified as risk factors for stroke, the genetic basis for the disease is unknown.

26 Mar 2018

New computational method helps to identify tumor cell mutations with greater accuracy

A new computational method developed by researchers at the New York Genome Center allows scientists to identify rare gene mutations in cancer cells with greater accuracy and sensitivity than currently available approaches.

22 Mar 2018

Agendia receives CE mark for MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing-based MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.

22 Mar 2018

Neuroscientists move closer to developing tools for deciphering brain function

A team of University of Missouri neuroscientists are inching closer to developing the tools needed to decipher the brain.

21 Mar 2018

Protein profiling reveals new prostate cancer mechanisms

A study by the University of Tampere in Finland used protein profiling to find new prostate cancer mechanisms that are not shown by aberrations at the genomic level. Several new potential biomarkers of prostate cancer were also found.

21 Mar 2018

Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis

Today (8 January 2018) at the annual J.P. Morgan Healthcare Conference, Edico Genome and Genomics England announced a new partnership to strengthen the accuracy and consistency of next-generation sequencing data analysis in Genomics England’s Rare Disease Pilot.

From Genomics England 20 Mar 2018

‘Fast track’ project shows promising results in cancer whole genome analyses

One key aim of the 100,000 Genomes Project is to improve cancer care for NHS patients. Whole genome sequencing in cancer can enable clinicians to choose better treatments and improve outcomes for patients through personalized medicine.

From Genomics England 20 Mar 2018

Researchers find way to identify undiagnosed genetic diseases in electronic health records

Patients diagnosed with heart failure, stroke, infertility and kidney failure could actually be suffering from rare and undiagnosed genetic diseases.

16 Mar 2018

Medical University of Vienna to partner with bio.logis GIM in pharmacogenetics

Within the framework of U-PGx, an EU project for promoting the use of pharmacogenetic insights in healthcare, the Medical University of Vienna will implement the Genetic Information Management Suite developed by bio.logis Genetic Information Management GmbH.

14 Mar 2018

Scientists discover 36 previously unknown genes implicated in heart failure

One in four deaths in the United States each year are due to heart disease, according to the Centers for Disease Control and Prevention. It's the leading killer of both men and women, but the disease's genetic complexity makes it difficult to treat.

8 Mar 2018

Study identifies genetic defect linked to heart failure in African Americans

Heart failure is more common, develops earlier and results in higher rates of illness and death in African Americans than in whites.

7 Mar 2018

NETRF awards six new research grants to improve treatments for neuroendocrine tumors

The Neuroendocrine Tumor Research Foundation today awarded six new research grants totaling $1.85 million to leading academic institutions around the world.

5 Mar 2018

New PET imaging agent allows early detection of prostate cancer relapse

An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level).